Kyowa Kirin set to fall by daily limit; ends trial on safety

Kyowa Kirin set to fall by daily limit; ends trial on safety

Kyowa Kirin Announces Discontinuation of Experimental Drug Trials Amid Safety Concerns

Kyowa Kirin (TSE:4151) has announced the termination of all clinical trials for its experimental monoclonal antibody, rocatinlimab, following a safety review that indicated potential risks may outweigh benefits for patients. The drug was under investigation for treating moderate-to-severe atopic dermatitis, prurigo nodularis, and asthma. The decision follows a planned safety update from the global clinical program, prompting Kyowa Kirin to discontinue collaboration with Amgen, which had previously co-developed the therapy according to Reuters. The company will now retain full control over the program, including regulatory filings and future commercialization efforts as reported.

The announcement comes amid a period of mixed valuation signals for Kyowa Kirin's stock. As of March 3, 2026, the shares closed at ¥2,504.5, reflecting a 5.4% decline over the past seven days and a 0.4% drop year-to-date. A discounted cash flow (DCF) analysis suggests the stock is undervalued by 52.6% relative to projected future cash flows, which estimate an intrinsic value of ¥5,289.1 per share. However, the company's price-to-earnings (P/E) ratio of 35.9x exceeds both the pharmaceutical industry average (16.4x) and Simply Wall St's proprietary Fair Ratio of 24.5x, indicating overvaluation on an earnings multiple basis.

The termination of rocatinlimab trials underscores the inherent risks in pharmaceutical R&D, where late-stage setbacks can significantly impact investor sentiment. While Kyowa Kirin's long-term fundamentals remain tied to its broader pipeline and partnerships, the decision to halt this program may influence near-term market perceptions. Investors are advised to monitor regulatory updates and the company's strategic pivot in response to this development.

This article is for informational purposes only and does not constitute financial advice. Investors should conduct further due diligence and consider their individual risk profiles before making decisions.

Source 1: Yahoo Finance. Source 2: Reuters. Source 3: Reuters.